Home » Newsletters » BioWorld Science

BioWorld Science

Jan. 20, 1998

View Archived Issues

CV Therapeutics seeks permission to move CVT-510 to clinical trials

LeuTech completes phase I

MedImmune and SmithKline Beecham finalize vaccine agreement

AxyS launches technologies division

Inhale and Lilly to codevelop pulmonary delivery formulation

Optex awarded Phase II SBIR grant

Novel semisynthetic macrolides prepared at Abbott

Lexicon and ZymoGenetics sign functional genomics agreement

Lilly acquires rights to Sibia's drug discovery technology

Lilly discloses new agents for influenza

MS&D reveals new class of antimigraine agents

VEGF and FGF receptor TK inhibitors from Zeneca

SmithKline Beecham develops Lp-PLA2 inhibitors for atherosclerosis

Novel atypical antipsychotic agent presented by Lundbeck

Novel gene therapy for chemoprotection of bone marrow found safe in early clinical trials

New HIV vaccine from VaxGen cleared for phase I/II studies

Lovenox/Clexane receives approvals in 11 additional countries

Zeneca commits to development of Zomig line extensions

Sheffield proceeds with development of respiratory drugs in its MSI

Preclinical efficacy results reported for Maruho's NSAID

CVT-313: promising antiproliferative agent that inhibits CDK2

Filgrastim reduces neutropenia and morbidity associated with AML treatment

Pharmacopeia achieves milestone in collaboration with Daiichi

BioTime lays groundwork for Japanese licensing of Hextend

Controlled-release tramadol under development

IL-12 offers new approach to BMT in leukemia patients

Ribozyme, Parke-Davis intend to collaborate

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for March 10, 2026.
Cas and effect: Merck’s phase III ripples HIF-2α space
BioWorld
Oddsmakers wasted no time figuring the market chances after Merck & Co. Inc. rolled out data from the phase III Litespark-011 study testing its oral...
Brain’s hidden tau-clearing pathway uncovered
BioWorld Science
Researchers at INSERM and collaborators have identified hypothalamic tanycytes as mediators of tau clearance and shown that their structural and genetic...
News in brief
BioWorld Asia
BioWorld Asia briefs for March 10, 2026
MSD synthesizes α-synuclein PET agents
BioWorld Science
Merck Sharp & Dohme LLC (MSD) has prepared and tested new positron emission tomography (PET) agents for binding and imaging α-synuclein (SNCA) for the diagnosis...